All News
Filter News
Found 808,684 articles
-
International Isotopes Inc. Announces Fiscal Results for the Third Quarter and First Nine Months of 2023
11/14/2023
International Isotopes Inc. announces its financial results for the three- and nine-month periods ended September 30, 2023.
-
Repligen Announces Publication of the Company’s 2022 Sustainability Report
11/14/2023
Repligen Corporation today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.
-
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis(Phase II Multicenter Study is Proceeding Well with High Anticipation)
11/14/2023
XBiotech announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.
-
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
11/14/2023
SAB Biotherapeutics, Inc. today announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million.
-
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
11/14/2023
Shattuck Labs, Inc. announced that company management will participate in the 6th Annual Evercore ISI HealthCONx Conference being held November 28-30, 2023.
-
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
11/14/2023
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update.
-
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
11/14/2023
Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer.
-
PetVivo Reports Second Quarter of Fiscal 2024 Financial Results
11/14/2023
PetVivo Holdings, Inc. announces financial results for the three months ended September 30, 2023.
-
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/14/2023
DMK Pharmaceuticals Corporation today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate developments.
-
HSS Presents New Reproductive Health Research at the ACR Convergence 2023
11/14/2023
At this year's American College of Rheumatology annual meeting, Hospital for Special Surgery presented a number of important studies focused on reproductive health for patients with systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases, including issues related to fertility, sexual function, use of contraception and HPV vaccination.
-
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
11/14/2023
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023.
-
Largest Commercial Payers in Four States Expand Patient Access to Centinel Spine's prodisc® L
11/14/2023
Centinel Spine®, LLC announced the adoption of Carleon's Clinical Appropriateness Guidelines-Musculoskeletal Spine Surgery Criteria by the largest payers in Illinois, Texas, New Mexico, and Oklahoma—representing over 14 million covered lives.
-
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
11/14/2023
Entera Bio Ltd. today reported corporate updates and financial results for the third quarter ended September 30th, 2023.
-
AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD, A Phase 3 Early Alzheimer’s Disease Registration Trial
11/14/2023
AriBio Co., Ltd. announces the global expansion of the POLARIS-AD study, a phase 3 early Alzheimer’s disease trial into the European Union, United Kingdom, Korea and China.
-
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
11/14/2023
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2023, and provided a corporate update.
-
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
11/14/2023
GeoVax Labs, Inc. announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine.
-
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
11/14/2023
Syros Pharmaceuticals today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
-
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
11/14/2023
IMUNON, Inc. announces that Jean Boyer, Ph.D., vice president of preclinical research and development, will highlight the Company’s vaccine development work in a presentation at the Vaccines Summit-2023 underway in Boston.
-
IQVIA Announces Offering of Senior Secured Notes - November 14, 2023
11/14/2023
IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc., intends to raise $500,000,000 through an offering of senior secured notes due 2029.
-
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
11/14/2023
Shuttle Pharmaceuticals Holdings, Inc. today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.